Sitagliptin
Polycystic Ovary Syndrome
Peking University Third HospitalSmall moleculePhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 68/ 100
- Competitive Position
- 73/ 100
Competitive context
65 Active assets in the Polycystic Ovary Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Hcg Eman Basuni Ebrahim Mowad | Phase 4 | BBB |
Liraglutide Peking University Third Hospital | Phase 4 | BBB |
Semaglutide Methodist Health System | Phase 4 | BBB |
FOLLITROPIN BETA Universitair Ziekenhuis Brussel | Phase 4 | BBB |
Drospirenone Ege University | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Sitagliptin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →